Sonova (OTCMKTS:SONVY) Reaches New 52-Week High – Should You Buy?

Sonova Holding (OTCMKTS:SONVY)’s share price reached a new 52-week high during trading on Monday. The company traded as high as $67.13 and last traded at $67.13, with a volume of 2,322 shares. The stock had previously closed at $66.33.

Analyst Upgrades and Downgrades

Several brokerages recently commented on SONVY. Citigroup reissued a “sell” rating on shares of Sonova in a research note on Friday, July 24th. The Goldman Sachs Group upgraded shares of Sonova from a “hold” rating to a “buy” rating in a research note on Thursday, October 8th. Morgan Stanley upgraded Sonova from an “underweight” rating to an “equal weight” rating in a research report on Tuesday, June 23rd. Finally, UBS Group raised shares of Sonova from a “hold” rating to a “buy” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Sonova currently has an average rating of “Moderate Buy”.

Sonova Price Performance

The company’s fifty day moving average price is $59.41 and its two-hundred day moving average price is $52.91. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.43 and a current ratio of 1.75.

About Sonova

Sonova Holding AG is a Switzerland-based hearing-care company that develops, manufactures and distributes solutions for people with hearing loss. Its portfolio includes hearing aids, cochlear implants, hearing implants, wireless communication products and related accessories and services.

The company markets products under several brands, including Phonak, Unitron and Advanced Bionics. Sonova also operates hearing-care businesses and retail networks that provide hearing assessments, device fitting, rehabilitation support and after-sales services.